Hepatits B Vaccine (233961 Sci-B-Vac-002)

The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults.


Register Today!.

Trial Information

Start Date18 April 2018
End Date19 May 2019
Trial Duration1 Year
Number of Visits6 In-Person
Lead CRCAdam Pawluch

For additional information
on this trial contact: